WHWK

Whitehawk Therapeutics develops antibody drug conjugates (ADCs), which are a class of targeted cancer therapies that combine antibodies with toxic payloads to attack cancer cells. The company has a portfolio of three ADC candidates in early-stage development, with plans to submit an investigational new drug application for HWK-206 by mid-2026 and to release Phase 1 clinical trial data for HWK-007 and HWK-016 in the first half of 2027. Based on current cash and investments, Whitehawk expects to fund operations into 2028.

Pipeline

Catalyst Calendar